Transcriptional analysis on biomarkers of liver injury induced by anti-tuberculosis drugs

Transcriptional analysis on biomarkers of liver injury induced by anti-tuberculosis drugs

ObjectiveThe study utilized human transcriptome microarray to explore biomarkers for diagnosing drug-induced liver injury （DILI） caused by anti-tuberculosis drugs.MethodsA 6-month follow-up study was conducted on 152 patients treated with anti-tuberculosis drugs in designated hospitals in Shanghai....

Full description

Bibliographic Details
Main Authors:	LI Chen, WANG Yanqin, HUO Qian, SHUAI Yi, TAO Gonghua, HONG Xinyu, XIAO Ping
Format:	Article
Language:	zho
Published:	Shanghai Preventive Medicine Association 2023-02-01
Series:	Shanghai yufang yixue
Subjects:	anti-tuberculosis drug hepatotoxicity biomarker transcriptome enrichment pathway analysis
Online Access:	http://www.sjpm.org.cn/article/doi/10.19428/j.cnki.sjpm.2023.22327

Similar Items

Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China
by: Wu Shanshan, et al.
Published: (2012-06-01)

Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity
by: Mohammed A. Agha, et al.
Published: (2015-01-01)

Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis [Hepatotoxicity Pharmacogenomic of Anti Tuberculosis Drugs]
by: Andri Dwi Wahyudi, et al.
Published: (2015-09-01)

Frequency of Hepatotoxicity in Pulmonary Tuberculosis Patients taking Anti-Tuberculosis Therapy
by: Farkhanda Noureen, et al.
Published: (2017-07-01)

Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers
by: Nguyen Ky Phat, et al.
Published: (2023-10-01)

Transcriptional Biomarkers for Treatment Monitoring of Pulmonary Drug-Resistant Tuberculosis: Protocol for a Prospective Observational Study in Indonesia
by: Ida Parwati, et al.
Published: (2022-10-01)

Validity and reliability of “Short-questionnaire of tuberculosis patients’ knowledge about anti-tuberculosis and hepatotoxicity” (SQ-KSH-TB)
by: Dyah Aryani Perwitasari, et al.
Published: (2023-03-01)

Treatment Management in Hepatitis and Tuberculosis Coexistence
by: Neslihan Köse Kabil, et al.
Published: (2025-01-01)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
by: Marta Moreno-Torres, et al.
Published: (2022-06-01)

Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis
by: Chang Ho Kim, et al.
Published: (2023-04-01)

Decoding differentially expressed genes to identify potential immunity associated biomarkers in Tuberculosis: An integrative bioinformatics approach
by: Ankur Datta, et al.
Published: (2024-12-01)

Plasma Circular RNAs hsa_circ_0001953 and hsa_circ_0009024 as Diagnostic Biomarkers for Active Tuberculosis
by: Zikun Huang, et al.
Published: (2018-08-01)

Drug-induced liver injury (DILI) - mechanisms and diagnostic
by: Marta Małysz, et al.
Published: (2022-10-01)

Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity
by: Jinchun Sun, et al.
Published: (2014-07-01)

The Kynurenine/Tryptophan Ratio Is a Sensitive Biomarker for the Diagnosis of Pediatric Tuberculosis Among Indian Children
by: Jeffrey A. Tornheim, et al.
Published: (2022-01-01)

The Effects of Livercare Tablet [Combination of Milk Thistle, Dandelion, Barberry, Tumeric (Curcumin), and Artichoke] in Prevention of Anti-Tuberculosis Drugs-Induced Hepatotoxicity: A Randomized Controlled Clinical Trial
by: Mohammadreza Yazdani, et al.
Published: (2021-01-01)

Some Peculiarities of Modern Comorbid Tuberculosis Therapy
by: V. M. Kolomiets, et al.
Published: (2023-02-01)

Sex-specific blood-derived RNA biomarkers for childhood tuberculosis
by: Preethi Krishnan, et al.
Published: (2024-07-01)

A true challenge: Disseminated tuberculosis with tuberculous meningitis in a patient with underlying chronic liver disease
by: Harika Kalangi, et al.
Published: (2024-01-01)

Ivermectin drug induced liver injury
by: Mark Sonderup, et al.
Published: (2023-06-01)

The Use of Nootropic Drugs to Reduce Toxic Reactions in Rats to a Combination of Anti-Tuberculosis Drugs
by: G. N. Mozhokina, et al.
Published: (2024-12-01)

Herbo-vitamin medicine Livogrit Vital ameliorates isoniazid induced liver injury (IILI) in human liver (HepG2) cells by decreasing isoniazid accumulation and oxidative stress driven hepatotoxicity
by: Acharya Balkrishna, et al.
Published: (2024-11-01)

Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods
by: Xiaohong Li, et al.
Published: (2022-11-01)

Novel RNA biomarkers improve discrimination of children with tuberculosis disease from those with non-TB pneumonia after in vitro stimulation
by: Ortensia Vito, et al.
Published: (2024-09-01)

Cargoes of exosomes function as potential biomarkers for Mycobacterium tuberculosis infection
by: Nan Wang, et al.
Published: (2023-10-01)

Biomarkers of Hepatic Toxicity: An Overview
by: Simran Thakur, Pharm.D, et al.
Published: (2024-01-01)

Biomarker discovery for tuberculosis using metabolomics
by: Yi Yu, et al.
Published: (2023-02-01)

The association and interactions of malnutrition, micronutrients, and drug therapy in the management of tuberculosis
by: Muhammad Maaz, et al.
Published: (2024-06-01)

Parameters of hepatotoxic reactions caused by the combination of first line anti-tuberculosis drugs in rats with different acetylation phenotypes
by: G. N. Mozhokina, et al.
Published: (2020-08-01)

Effects of Anti-Tuberculosis Drugs on Lipid Profile in Pulmonary Tuberculosis Patients
by: Nisar Ahmed, et al.
Published: (2022-01-01)

Astaxanthin effect on apoptotic biomarkers in methotrexate-induced liver injury
by: Sarah Saad Hamdan, et al.
Published: (2022-10-01)

Diagnostic biomarkers for active tuberculosis: progress and challenges
by: Betânia M F Nogueira, et al.
Published: (2022-10-01)

Diagnostic markers reflecting dysregulation of the host response in the transition to tuberculosis disease
by: Gunilla Källenius, et al.
Published: (2024-04-01)

Effect of Genetic Polymorphism of the Enzyme Genes Responsible for Biotransformation of Antituberculous Drug on the Risk of Hepatotoxic Reaction in Patients with Tuberculosis
by: A. V. Kazakov, et al.
Published: (2020-05-01)

Differential gene expression analysis pipelines and bioinformatic tools for the identification of specific biomarkers: A review
by: Diletta Rosati, et al.
Published: (2024-12-01)

Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population
by: Débora Christina Ricardo Oliveira Fernandes, et al.
Published: (2015-04-01)

Antigen-specific chemokine profiles as biomarkers for detecting Mycobacterium tuberculosis infection
by: Weicong Ren, et al.
Published: (2024-03-01)

Pharmacological correction of hepatotoxicity induced by anti-tuberculosis drugs
by: D. S. Sukhanov, et al.
Published: (2023-04-01)

Meta-analysis of active tuberculosis gene expression ascertains host directed drug targets
by: Nirmaladevi Ponnusamy, et al.
Published: (2022-10-01)

Influence of the Acetylation Type on the Incidence of Isoniazid-Induced Hepatotoxicity in Patients with Newly Diagnosed Pulmonary Tuberculosis
by: N. M. Krasnova, et al.
Published: (2020-11-01)